Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Clinical trial NCT04029350 · UNKNOWN
Trial details
- NCT number
- NCT04029350
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-31
- Primary completion
- 2020-01-31
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.